Trademark for India’s First Indigenous Tumour Antigen (E)
In a significant development, National Institute of Immunology (NII) functioning under the Department of Biotechnology, Govt of India, has received a trademark for India’s first indigenous tumour antigen. The antigen called SPAG9 was discovered by Dr. Anil Suri of NII in 1998, and is being used in cancer immunotherapy to treat cervical and ovarian cancer. Now the antigen will also be used in clinical trials relating to breast cancer.
